Ibandronic Acid Teva

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

ibandronska kislina

Available from:

Teva Pharma B.V.

ATC code:

M05BA06

INN (International Name):

ibandronic acid

Therapeutic group:

Zdravila za zdravljenje bolezni kosti

Therapeutic area:

Breast Neoplasms; Neoplasm Metastasis; Fractures, Bone; Osteoporosis, Postmenopausal

Therapeutic indications:

Ibandronic acid 50mgIbandronic Kislina Teva je indicirano za preprečevanje skeletne dogodkov (patološki zlomi, kosti zapleti, ki zahtevajo radioterapija ali kirurški poseg) pri bolnikih z rakom dojk in kostni zasevki. Ibandronic acid 150mgTreatment of osteoporosis in postmenopausal women at increased risk of fracture. Zmanjšanje tveganja za zlome vretenc je bilo dokazano, učinkovitosti na vratu femoralne zlome ni bila ugotovljena.

Product summary:

Revision: 12

Authorization status:

Pooblaščeni

Authorization date:

2010-09-17

Patient Information leaflet

                                33
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Teva B.V.
Swensweg 5
2031 GA Haarlem
Nizozemska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/10/642/001
28 filmsko obloženih tablet
EU/1/10/642/002
84 filmsko obloženih tablet
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
Predpisovanje in izdaja zdravila je le na recept.
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Ibandronska kislina Teva 50 mg filmsko obložene tablete
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC
SN
NN
34
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
PRETISNI OMOTI
1.
IME ZDRAVILA
Ibandronska kislina Teva 50 mg filmsko obložene tablete
ibandronska kislina
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Teva B.V.
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
DRUGI PODATKI
Pon
Tor
Sre
Čet
Pet
Sob
Ned
35
PODATKI NA ZUNANJI OVOJNINI
ŠKATLA
1.
IME ZDRAVILA
Ibandronska kislina Teva 150 mg filmsko obložene tablete
ibandronska kislina
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena filmsko obložena tableta vsebuje 150 mg ibandronske kisline (v
obliki natrijevega monohidrata).
3.
SEZNAM POMOŽNIH SNOVI
4.
FARMACEVTSKA OBLIKA IN VSEBINA
filmsko obložena tableta
1 filmsko obložena tableta
3 filmsko obložene tablete
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
_ _
Tablete ne smete sesati, žvečiti ali drobiti.
Tableta za odmerjanje enkrat mesečno.
Zapišite si datum, ko ste vzeli tableto.
Mesec 1 __/__/__
Mesec 2 __/__/__
Mesec 3 __/__/__
Pred uporabo preberite priloženo navodilo!
peroralna uporaba
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
36
9.
POSEBNA NA
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Ibandronska kislina Teva 50 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ena filmsko obložena tableta vsebuje 50 mg ibandronske kisline (v
obliki natrijevega monohidrata).
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
filmsko obložena tableta
Bela, bikonveksna, filmsko obložena tableta v obliki kapsule, z
vtisnjeno oznako »50« na eni strani in
gladka na drugi.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Ibandronska kislina Teva je pri odraslih indicirano za
preprečevanje z okostjem povezanih
dogodkov (patološki zlomi, zapleti, pri katerih je potrebno
obsevanje, ali kirurški poseg) pri bolnikih z
rakom dojke in metastazami v kosteh.
4.2
ODMERJANJE IN NAČIN UPORABE
Zdravljenje z zdravilom Ibandronska kislina Teva sme uvesti samo
zdravnik, ki ima izkušnje pri
zdravljenju raka.
Odmerjanje
Priporočeni odmerek je ena 50 mg filmsko obložena tableta dnevno.
_Posebne skupine bolnikov _
_Okvara jeter _
Prilagajanje odmerka ni potrebno (glejte poglavje 5.2).
_Okvara ledvic _
Pri bolnikih z blago ledvično okvaro (CLcr ≥ 50 in < 80 ml/min)
prilagajanje odmerkov ni potrebno.
Pri bolnikih z zmerno ledvično okvaro (CLcr ≥ 30 in < 50 ml/min) se
priporoča zmanjšanje odmerka
na eno 50 mg filmsko obloženo tableto vsak drugi dan (glejte poglavje
5.2).
Pri bolnikih s hudo ledvično okvaro (CLcr < 30 ml/min) je
priporočeni odmerek ena 50 mg filmsko
obložena tableta enkrat tedensko. Glejte zgornja navodila za
odmerjanje.
_Starejša populacija (> 65 let) _
Prilagajanje odmerkov ni potrebno (glejte poglavje 5.2).
_Pediatrična populacija _
Varnost in učinkovitost zdravila Ibandronska kislina Teva pri otrocih
in mladostnikih, mlajših od
18 let, nista bili dokazani. Podatkov ni na voljo. (Glejte poglavji
5.1 in 5.2).
Način uporabe
3
Za peroralno uporabo.
Tablete Ibandronska kislina Teva je treba vzeti zjutraj na prazen
želodec (po najmanj 6 urah brez
obroka) in pred prvim dnevnim o
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 22-11-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 22-11-2022
Public Assessment Report Public Assessment Report Bulgarian 30-09-2015
Patient Information leaflet Patient Information leaflet Spanish 22-11-2022
Public Assessment Report Public Assessment Report Spanish 30-09-2015
Patient Information leaflet Patient Information leaflet Czech 22-11-2022
Public Assessment Report Public Assessment Report Czech 30-09-2015
Patient Information leaflet Patient Information leaflet Danish 22-11-2022
Public Assessment Report Public Assessment Report Danish 30-09-2015
Patient Information leaflet Patient Information leaflet German 22-11-2022
Public Assessment Report Public Assessment Report German 30-09-2015
Patient Information leaflet Patient Information leaflet Estonian 22-11-2022
Public Assessment Report Public Assessment Report Estonian 30-09-2015
Patient Information leaflet Patient Information leaflet Greek 22-11-2022
Public Assessment Report Public Assessment Report Greek 30-09-2015
Patient Information leaflet Patient Information leaflet English 22-11-2022
Public Assessment Report Public Assessment Report English 30-09-2015
Patient Information leaflet Patient Information leaflet French 22-11-2022
Public Assessment Report Public Assessment Report French 30-09-2015
Patient Information leaflet Patient Information leaflet Italian 22-11-2022
Public Assessment Report Public Assessment Report Italian 30-09-2015
Patient Information leaflet Patient Information leaflet Latvian 22-11-2022
Public Assessment Report Public Assessment Report Latvian 30-09-2015
Patient Information leaflet Patient Information leaflet Lithuanian 22-11-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 22-11-2022
Public Assessment Report Public Assessment Report Lithuanian 30-09-2015
Patient Information leaflet Patient Information leaflet Hungarian 22-11-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 22-11-2022
Public Assessment Report Public Assessment Report Hungarian 30-09-2015
Patient Information leaflet Patient Information leaflet Maltese 22-11-2022
Public Assessment Report Public Assessment Report Maltese 30-09-2015
Patient Information leaflet Patient Information leaflet Dutch 22-11-2022
Public Assessment Report Public Assessment Report Dutch 30-09-2015
Patient Information leaflet Patient Information leaflet Polish 22-11-2022
Public Assessment Report Public Assessment Report Polish 30-09-2015
Patient Information leaflet Patient Information leaflet Portuguese 22-11-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 22-11-2022
Public Assessment Report Public Assessment Report Portuguese 30-09-2015
Patient Information leaflet Patient Information leaflet Romanian 22-11-2022
Public Assessment Report Public Assessment Report Romanian 30-09-2015
Patient Information leaflet Patient Information leaflet Slovak 22-11-2022
Public Assessment Report Public Assessment Report Slovak 30-09-2015
Patient Information leaflet Patient Information leaflet Finnish 22-11-2022
Public Assessment Report Public Assessment Report Finnish 30-09-2015
Patient Information leaflet Patient Information leaflet Swedish 22-11-2022
Public Assessment Report Public Assessment Report Swedish 30-09-2015
Patient Information leaflet Patient Information leaflet Norwegian 22-11-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 22-11-2022
Patient Information leaflet Patient Information leaflet Icelandic 22-11-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 22-11-2022
Patient Information leaflet Patient Information leaflet Croatian 22-11-2022
Public Assessment Report Public Assessment Report Croatian 30-09-2015

Search alerts related to this product